SRC and melanoma: Src tyrosin kinase inhibitors have been explored as potential new therapeutic agents in a variety of malignancies such as melanoma (one such inhibitor demonstrating in vitro activity on a variety of melanoma cells, including some BRAFV600 mutant cells [11], but a report that src inhibition would induce melanogenesis in melanoma cells has also been published [12]), papillary thyroid carcinoma [13], clear-cell renal carcinoma [14], pancreatic [15], or ovarian cancer [16].